Germany's Merck Group appears set to build on its strong showing in India. Belén Garijo, CEO of Healthcare at Merck KGAA, tells Scrip about efforts to "consumerize" the firm's primary care business, how Erbitux is the "backbone" on which the company will build its oncology presence, and plans to roll out new products including the clinical stage immune-oncology asset avelumab, in India.
Germany's Merck KGAA appears to have put in place the key elements to catapult growth in its India business.
It has made significant investments to bring scale to its manufacturing capabilities; its healthcare business now operates under a "renewed" leadership; and a "different" operating model is expected to see...